Authors


A. Jo Chien, MD

Latest:

Dr. Chien on Tucatinib in HER2+ Breast Cancer

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.


A. Karim Kader, MD, PhD

Latest:

Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO Trial

A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.



A. Keith Stewart, MB ChB

Latest:

Final Thoughts on Case Study and Treating Multiple Myeloma

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.




A. Oliver Sartor, MD

Latest:

Dr Sartor on Efficacy and Safety of Lutetium Lu 177 Vipivotide Tetraxetan in Taxane-Naive mCRPC

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.



Aakanksha Prasad Asija, MD, MPH

Latest:

When Patients Refuse Treatment for Their Cancer

Quoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.


Aarati Rao, MD

Latest:

A Day In the Life of a Pediatric Oncologist

As a practicing pediatric oncologist at an academic institute, every morning begins with optimism and a quest to win the day.




Aaron E. Katz, MD, FACS

Latest:

Dr. Katz on Redefining Risk Stratification in Prostate Cancer

Aaron E. Katz, MD, FACS, discusses redefining risk stratification for men with prostate cancer.


Aaron Gerds, MD

Latest:

Dr Gerds on the Importance of Evaluating Selinexor in JAK Inhibitor–Naive Myelofibrosis

Aaron Gerds, MD, discusses the importance of evaluating the efficacy and safety of selinexor in patients with JAK inhibitor–naive myelofibrosis, as assessed in the phase 1/3 XPORT-MF-034 trial.


Aaron Goodman, MD

Latest:

Dr. Goodman on the Need for Molecular Subtyping in T-Cell Lymphomas

Aaron Goodman, MD, discusses the need for molecular subtyping in T-cell lymphomas.


Aaron Logan, MD, PhD

Latest:

Dr. Logan Discusses Acalabrutinib in CLL

Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses acalabrutinib (Calquence) in chronic lymphocytic leukemia.


Aaron S. Mansfield, MD

Latest:

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.


Aaron S. Mansfield MD, Tobias Peikert, MD

Latest:

Potential Applications of Immune Checkpoint Blockade for Mesothelioma

Malignant pleural mesothelioma (MPM) is an inexorably progressive and almost universally fatal malignancy.


Aarti S. Bhardwaj, MD

Latest:

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.


Aashini Master, DO

Latest:

Dr. Master on the Mediterranean Diet in Relation to Breast Cancer Risk

Aashini Master, DO, assistant clinical professor, Division of Hematology/Oncology, University of California, Los Angeles Medical Center, discusses the Mediterranean diet in relation to breast cancer risk.


Abdenour Nabid, MD

Latest:

Dr. Nabid on a Shorter Duration of ADT in Prostate Cancer

Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.


Abdulraheem Yacoub, MD

Latest:

Exploring the Future of MF Treatment

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.


Abhinav Deol, MD

Latest:

Dr Deol on Potential Avenues for CAR T-Cell Therapy Research in Multiple Myeloma

Abhinav Deol, MD, discusses ongoing and potential research avenues for improving the use of CAR T-cell therapy in multiple myeloma.


Abigail L. Stockham, MD

Latest:

The Role of Radiation in the Management of Brain Metastases

In this review, the role of radiotherapy in the management of brain metastases is considered from a historical perspective, in the context of other treatment modalities, and with regard to different radiotherapy techniques.


Abigail S. Caudle, MD

Latest:

Dr. Caudle on Upcoming Breast Cancer Trial Results

Abigail S. Caudle, MD, Assistant Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, gives an overview of two trials in breast cancer.


Abraham Chachoua, MD

Latest:

Dr. Chachoua on Afatinib for Exon 19 Mutation in Lung Cancer

Abraham Chachoua, MD, associate director of cancer services at NYU Langone Medical Center, talks about targeted treatment for mutations in non-small cell lung cancer and adenocarcinoma.


​Carmela Hoefling, RN, MSN, APN-C, AOCNP

Latest:

Carmela Hoefling Discusses Effects of Malnutrition During Surgery

Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.


Adam Brufsky,MD

Latest:

Dr Brufsky on Unmet Needs and Unanswered Questions in HR+/HER2– Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses the remaining questions following the FDA approval of capivasertib/fulvestrant in HR+/HER2- breast cancer.



Adam D. Cohen, MD

Latest:

Dr Cohen on Efforts Needed to Unmet Needs in R/R Multiple Myeloma

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.